Cambridge, UK – 13 November 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial is due to recruit up to 30 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial data readouts are expected by the end of 2025.
Ulcerative colitis, an inflammatory bowel disease, is a debilitating…
06 November 2024 - Partnerships and alliances with external organisations have always been a vital route to growth for healthcare and life sciences, but unfortunately, they don’t always meet their aspirations and objectives. Business transformation expert, Mohi Khan, highlights the key principles for a successful partnership or collaborative relationship to deliver value.
Alliances and partnership spectrum
The healthcare and life sciences sector employs a wide spectrum of partnership arrangements and models. These range from simple, contractual arrangements to mergers and…
30 October 2024 - Boehringer submitted a VAT refund claim to HMRC for £21,488,167 covering an initial six-year period. This amount is potentially a drop in the ocean compared to the NHS’s projected £19bn expenditure on medicines each year.
The health system in the UK, similar to many countries, operates a scheme whereby pharmaceutical distributors pay a rebate against their wholesale supply of medicines into the public health system. The UK’s own scheme is the Voluntary Scheme for Branded Medicines Pricing, Access and Growth or ‘VPAG’ and is largely seen to help the state maintain the…
London 14th November 2024: Kadans Science Partner is excited to today announce the official opening of their new state-of-the-art laboratory building MAYDE, 5-10 Brandon Road.
Located in King’s Cross, London, MAYDE is the most recent high-specification office and laboratory building to join the world-famous Knowledge Quarter. This new laboratory scheme of 114,000 sq ft includes high-quality good-manufacturing-practices (GMP) pilot plant facilities and is the only space in London offering GMP manufacturing facilities alongside R&D and office space. This includes one floor…
Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories
Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to accelerate and de-risk clinical progression of drug candidates
Supports up to 18 data replicates and simulation of both intravenous and oral dosing routes
Cambridge, UK, 14 November 2024: CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18.…
Selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics
Consortium funded by Horizon Europe, the largest European research and innovation program
Cambridge, UK, and Boston, MA, USA, 12 November 2024: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, announced it has been invited to join EVEREST, a leading European consortium. The consortium’s objective is to advance EV research, innovation…
Cambridge, UK, 12th November 2024: Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created role of Chief Scientific & Innovation Officer.
Louise has almost 30 years’ experience working across the health and life sciences spectrum, working within academia, biotech and medium and large pharmaceutical organisations; from target discovery and R&D through to product launch and lifecycle management. Most recently Louise led the commercial…
Assembling the Technology-People-Money Trinity at the Genesis of Your SuccessWhilst different stakeholders may define value differently, translating the outcomes of leading-edge scientific research into value creation for all, including patients, investors, entrepreneurs, scientists, healthcare systems, and governments, requires excellence. Excellence in terms of the technology/product, people/team and investors/partners. Each year, Genesis is built to enable attendees to build their essential Life Science Trinity and why it is so valuable to attend.
Read more here
London, November 12, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with IMU Biosciences and is pleased to announce the placements of Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer. Founder and former Chief Executive Officer Dr. Adam Laing will assume the roles of President and Chief Scientific Officer.IMU Biosciences is a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine.Dr.…
📖 Read November's eNews here ✅ Tony Jones, CEO, One Nucleus - Partnering, Policies and Parties✅ Genesis Conference App Now Open! Start Your Networking Here...✅ New Government Delivers Optimism and Concern for the Region’s Life Sciences by Tony Jones✅ CRISPR – A Twist in the Tale in the Ongoing Patent Battle in Europe, by Appleyard Lees IP LLP✅ European Rare Disease M&A Activity in 2024 Whitepaper from PharmaVentures✅ The Power of Belonging by Alicia Gailliez, One Nucleus✅ What Happened at ON Helix 2024? Read the Review✅ Visualising One Nucleus Members Around the World – A New…